Real-World data shows triple inhaler eases COPD symptoms

NCT ID NCT06712563

Recruiting now Symptom relief Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025

Summary

This study pools data from multiple countries to see how a triple-combination inhaler (BGF) affects the daily lives of 2,000 people with moderate to severe COPD. Researchers will compare health status scores at 1, 3, and 12 months after starting treatment. The goal is to understand real-world benefits, not to test a new drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY DISEASE, CHRONIC OBSTRUCTIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
NOT_YET_RECRUITING

Mississauga, Canada
Research Site
RECRUITING

Hamburg, Germany
Research Site
RECRUITING

Athens, Greece
Research Site
RECRUITING

Milan, Italy
Research Site
RECRUITING

Tokyo, Japan
Research Site
NOT_YET_RECRUITING

Bucharest, Romania
Research Site
RECRUITING

London, United Kingdom

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY DISEASE, CHRONIC OBSTRUCTIVE